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Abstract
This Guidance for Priority Setting in Health Care (GPS-Health), initiated by the World Health Organization, offers a
comprehensive map of equity criteria that are relevant to health care priority setting and should be considered in
addition to cost-effectiveness analysis. The guidance, in the form of a checklist, is especially targeted at decision makers
who set priorities at national and sub-national levels, and those who interpret findings from cost-effectiveness analysis.
It is also targeted at researchers conducting cost-effectiveness analysis to improve reporting of their results in the light
of these other criteria.
The guidance was develop through a series of expert consultation meetings and involved three steps: i) methods and
normative concepts were identified through a systematic review; ii) the review findings were critically assessed in the
expert consultation meetings which resulted in a draft checklist of normative criteria; iii) the checklist was validated
though an extensive hearing process with input from a range of relevant stakeholders.
The GPS-Health incorporates criteria related to the disease an intervention targets (severity of disease, capacity to bene-
fit, and past health loss); characteristics of social groups an intervention targets (socioeconomic status, area of living,
gender; race, ethnicity, religion and sexual orientation); and non-health consequences of an intervention (financial pro-
tection, economic productivity, and care for others).
Keywords: Priority setting, Resource allocation, Cost-effectiveness, Equity, Population health
Introduction
Priority setting of health interventions should seek to achieve
health system goals, broadly defined as maximization of
health, reduction of inequities in health, and financial pro-
tection against the costs of ill health [1,2]. Present methods
for priority setting are poorly adapted to address the full
range of health system objectives. The main approach to
establishing health priority setting, cost-effectiveness ana-
lysis, addresses only the first objective of maximising
health [3-12]. How governments and other responsible au-
thorities balance health maximization with equity and fi-
nancial protection has far-reaching implications for what
health priorities are agreed and pursued [13]. Three is
therefore urgent need for a more explicit recognition of
these additional concerns.
The present Guidance for Priority Setting in Health
Care (GPS-Health) offers a checklist of equity criteria
that are relevant to health care priority setting and are
not adequately considered by cost-effectiveness analysis.
Decision-makers should carefully consider these criteria
alongside results of cost-effectiveness analyses when
making decisions on the funding of one intervention
and the refusal to fund another.
Process of guidance development
GPS-Health was develop through a series of expert con-
sultation meetings and involved three steps: i) Methods
and equity considerations were identified through a sys-
tematic review [14]. This review concluded that several
viable techniques to integrate equity concerns within
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CEA now exist, ranging from descriptive approaches to
quantitative methods. Two obstacles at the normative
level have impeded their use in decision making to date:
the multiplicity of concepts and values discussed under
the rubric of equity, and the lack of a widely accepted
normative source on which to ground controversial
value choices. Clarification of equity concepts and atten-
tion to procedural fairness may strengthen use of these
techniques in decision-making. ii) The expert group –
with representatives from the International Society on
Priorities in Health Care, WHO, the National Institute
for Health and Clinical Excellence (UK), decision makers
from low- and middle income countries, and ethicists
and health economists from various academic institu-
tions – met to validate and refine the list of proposed
normative criteria. iii) The draft document was pre-
sented to the International Society on Priority Setting in
Health and other interested stakeholder to improve the
recommendations. Input from this hearing process was
used in the final revision of the document.
Target groups and proposed use
The guidance is especially targeted at decision makers
who set priorities at national and sub-national levels and
who interpret findings from cost-effectiveness analysis. It
is intended to be used as a practical checklist that helps
them to make sure they have considered all the main is-
sues of equity that are not captured by cost-effectiveness
analysis. It is also targeted at researchers conducting
cost-effectiveness analysis to improve reporting of their
results in the light of these other criteria. Clinicians, and
others who want to participate in informed public de-
bate, may also benefit from this guidance.
The guidance is particularly useful if evidence exists
on the cost-effectiveness for a wide range of health inter-
ventions, and important choices need to be made on
which intervention to fund, and for whom. WHO’s
CHOICE project has produced a large database of the
cost-effectiveness of intervention, which could be one
possible starting point for assessing the range or depth
of services to be provided [15]. The Disease Control Pri-
orities Project is another source containing relevant
cost-effectiveness evidence [16]. Although special atten-
tion is given to low- and middle-income countries, this
guidance is relevant in all settings [17].
Principles for priority setting
Priority setting in health is inevitable in all countries
around the world. The choices a country makes will al-
ways positively or negatively affect some people in the
population it serves. Decision makers are therefore ac-
countable to justify their decisions to all those affected
and demonstrate that they are aligned with the country’s
social values concerning health maximization, health dis-
tribution, and financial protection.
Cost effectiveness analysis identifies how resources
should be allocated across health interventions so as to
maximize health benefits within a given budget, or rela-
tive to a threshold level of societal willingness to pay
[18]. Concerns about the distribution of health stem
from the idea that every person in society should have a
fair chance to live a long and healthy life [19]. This
principle can be further expressed in terms of vertical
equity (requiring the unequal treatment of relevantly un-
equal cases and pertaining to characteristics of the dis-
ease an intervention targets) and horizontal equity
(requiring equal treatment of relevantly equal cases and
pertaining to characteristics of social groups an interven-
tion targets) [20-22]. The use of either cost-effectiveness
analysis or equity analysis for priority setting may lead
to different policy recommendations. The key difference
is that the former is only concerned about the absolute
size of health gains, whereas the latter is concerned
about how these health gains are distributed among
members of the population. This may lead to striking
differences in e.g. provision of health interventions for
HIV/AIDS control, in which cost-effectiveness analysis
recommends a strategy of universal test and early treat-
ment as an efficient way to reduce the epidemic [23],
and equity analysis would suggest prioritizing treatment
of severely ill people, mobile treatment services in rural
service or food subsidies to poor people [24].
In addition, health interventions also have important
consequences outside the health sector, and these may
also determine whether certain interventions should be
considered priorities. Most importantly, countries may
wish to implement interventions that provide financial
protection to their populations, in order to reduce pov-
erty associated with ill health or catastrophic health
expenditures.
Criteria for priority setting
The GPS-Health distinguishes three groups of criteria
pertaining to i) the disease an intervention targets; ii)
the characteristics of the social group an intervention
targets; and iii) non-health consequences (Table 1).
Below we present rationales for consideration of these
criteria in the prioritisation of health interventions, in
addition to cost-effectiveness analysis. Several other cri-
teria were also considered, but excluded from the check-
list (see Appendix).
Group 1: disease-related criteria
For equity reasons, decision-makers may want to attach
special value to interventions that target severe health
conditions, people with a low capacity to benefit or with
large past health losses.
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Severity of health condition
Numerous studies of public preferences show that
people put a high value on interventions for particularly
severe health conditions, even when they are compara-
tively less effective than other alternatives [8,25,26].
Many ethical theories also defend giving additional
weight to health benefits distributed to those who are
worse off in terms of the severity of disease [27-30]. Se-
vere health conditions can refer to a) present health sta-
tus, b) future health status, or c) future health gap
compared with a reference standard of healthy life ex-
pectancy. Interventions for such severe conditions are
often cost-effective, but not always (see Example 1).
Example 1: Severity of disease and infliximab for fistu-
lising Crohn’s disease in UK:
In a recent recommendation from NICE on treatment
with infliximab for fistulising Crohn’s disease, the incre-
mental cost-effectiveness ratio compared to standard
care was found to be €30,300 per QALY gained, which is
around, or somewhat higher, than the recommended
threshold of approximately €30 000 per QALY gained
[31]. In the overall assessment, treatment with infliximab
was nevertheless recommended for fistulising Crohn’s
because the severity of the condition was considered so
high that it justified an adjustment of the threshold
typically set: “Although this ICER was considered to be
relatively high, the Committee considered the severity of
the disease and noted that there were few treatment
options available to these patients. The Committee
therefore concluded that a planned course of treatment
with infliximab for people with fistulising disease could
be cost effective if the definition of severe disease was
met.” [31].
This example shows that severity of disease sometimes
can be seen as an independent criterion for adjusting
judgments based on cost-effectiveness only. Other exam-
ples of particularly severe health conditions include
under-five deaths from infections and malnutrition, ma-
ternal deaths, severe maternal complications, chronic
schizophrenia, severe bipolar depression, suicide in
young age, traffic accidents, HIV, TB, cervical cancer in
young age, or severe congenital disorders.
Realization of potential
From the principle of health maximisation follows that
priority should be given to people who benefit most
from treatment. However, capacity to benefit is not the
only consideration because one may value realization of
potentials and wish to offer equal chances to people with
different potentials. Many ethicists argue that persons
with less treatable health conditions should have just as
much of a fair chance to benefit from health care
[32,33]. For example, if two potential organ transplant
recipients have a potential to benefit that differs, every-
thing else alike, health maximization requires that the
person with highest expected benefit should have the
organ [34]. By contrast, many argue that equity requires
that each be given as much of a fair chance as others
(for example through a weighted lottery) to realize their
Table 1 Priority-setting criteria to be considered in
conjunction with cost-effectiveness results
Group 1: disease and intervention criteria
Criteria Question
Severity Have you considered whether the
intervention has special value because of
the severity of the health condition
(present and future health gap) that the
intervention targets?
Realization of potential Have you considered whether the
intervention has more value than the
effect size alone suggests on the grounds
that it does the best possible for a patient
group for whom restoration to full health
is not possible?
Past health loss Have you considered whether the
intervention has special value because it
targets a group that has suffered
significant past health loss (e.g. chronic
disability)?
Group 2: criteria related to characteristics of social groups
Criteria Question
Socioeconomic status Have you considered whether the
intervention has special value because it
can reduce disparities in health associated
with unfair inequalities in wealth, income
or level of education?
Area of living Have you considered whether the
intervention has special value because it
can reduce disparities in health associated
with area of living?
Gender Have you considered whether the
intervention will reduce disparities in
health associated with gender?
Race, ethnicity, religion
and sexual orientation
Have you considered whether the
intervention may disproportionally affect
groups characterized by race, ethnicity,
religion, and sexual orientation?
Group 3: criteria related to protection against the financial and
social effects of ill health
Criteria Question
Economic productivity Have you considered whether the
intervention has special value because it
enhances welfare to the individual and
society by protecting the target
population’s productivity?
Care for others Have you considered whether the
intervention has special value because it
enhances welfare by protecting the target
population’s ability to take care of others?
Catastrophic health
expenditures
Have you considered whether the
intervention has special value because it
reduces catastrophic health expenditures
for the target population?
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potential. This egalitarian “fair chances” argument has
support in the general public and among societal deci-
sion makers in several jurisdictions [32,33].
Past health loss
Concern for past health loss, for example due to chronic
disability, is a criterion hitherto less discussed in the lit-
erature on priority setting. It derives its justification
from a concern for equal lifetime health: all persons
should have a fair chance to live a long and healthy life
due to the intrinsic importance of health and its instru-
mental value in enabling fulfilment of life plans [35].
Group 2: criteria related to characteristics of social groups
Equity in health related to characteristic of social groups
has been defined as “the absence of systematic dispar-
ities in health between social groups who have different
levels of underlying social advantage or disadvantage”
[36]. Targeting health interventions to disfavoured groups
may be viewed as appropriate when these compensate for
underlying factors such as the social determinants of
health [4], even when they are not cost-effective. In
resource-limited settings, social group factors can be par-
ticularly relevant in terms of socio-economic status, area
of residence, and gender.
Socioeconomic status
People with lower socioeconomic status (SES) should
have a fair chance to live a full healthy life. Health in-
equalities related to SES may be unfair when they are
the result of an unjust distribution of the socially con-
trollable factors affecting population health [6]. These
factors may include social determinants of health, trad-
itional public health measures, and personal medical
services. Health interventions to reduce these health in-
equalities, e.g. food subsidies for people living with HIV/
AIDS, hold therefore special value and deserve add-
itional priority (see Example 2) [6,37-40]. However, deci-
sion makers should also note that interventions outside
the health sector may represent a more effective way to
reduce health disparities, such as improving female edu-
cation (where relevant) or implementing effective regula-
tory or fiscal measures. Thus, disparities in health
associated with non-health determinants of health could
have far-reaching implications for judgments about re-
source allocation outside the health sector.
Example 2: Correcting for socio-economic inequality
in Sweden:
Swedish politicians responsible for health care in the
county councils (n = 449) were asked in a survey about
their opinions on trade-offs between interventions that
maximizes health vs. interventions that are less efficient
but eliminate social inequalities. The scenario assumed
that myocardial infarction mortality rate was 50% higher
among blue-collar workers than among white collar
workers, and that the most cost-effective intervention
(i.e. that saved most lives) did not reduce the inequality.
The Swedish politicians rejected to only maximise
health, and expressed their willingness to sacrifice 15 of
100 preventable deaths to reduce social inequalities [41].
The example illustrates the concept of opportunity cost
that is key to all thinking about fair and efficient distri-
bution. The opportunity cost of a health intervention is
the value of health forgone if resources are spent else-
where. The politicians were explicitly thinking about
how many extra people would die in order to help a dis-
advantaged group. Distribution of health benefits be-
tween socioeconomic groups matters to decision makers
and in this case decision makers rejected allocation
strictly according to cost-effectiveness rankings.
Area of residence
Inequalities in health associated with area of residence
are often seen as unacceptable and geographic equity is
an often-stated goal in national health policy documents.
People living in different areas should all have a fair
chance to live a full and healthy life, and this may mean
that priority should be given to interventions that target
those areas. Localization of clinics for HIV treatment is
one example where this criterion is relevant [42]. Be-
cause the provision of health care in rural areas, with
few people or long travel distances, can be considerably
more costly than in urban areas, achieving geographic
equity may imply relative loss in overall population
health gain [43].
Gender
In its most general form, men and women should have a
fair chance to live a full and healthy life. Since women
tend to have a longer life expectancy than men, but
lower health status over their lifetime, it is not possible
to provide general guidance on whether interventions
targeting men or women should be considered a priority.
Since there are forms of unfair treatment for women in
nearly all countries, however, a special check for gender-
related disparities should be considered. This concern is
especially relevant for reproductive health services and
interventions against domestic violence against women,
but also for road traffic injuries among young males and
tobacco control for men.
Race, ethnicity, religion, and sexual orientation
All people, independent of race, ethnicity, religion or
sexual orientation, should have a fair chance to live a full
and healthy life. This criterion is mainly a non-
discriminatory clause, referring to instances in which in-
terventions may be less effective or more costly in cer-
tain ethnic groups; prevention of cardiovascular disease
Norheim et al. Cost Effectiveness and Resource Allocation 2014, 12:18 Page 4 of 8
http://www.resource-allocation.com/content/12/1/18
among the Maori may be one example. Decision makers
should take this into account, and give special value to
interventions targeting those groups.
Group 3: criteria related to protection against the
financial and social effects of ill health
This third set of criteria refers to the financial and social
protection that some interventions offer [44]. Because of
these non-health consequences, these interventions hold
special value, and decision makers may sometimes want
to prioritize them even if they are not cost-effective.
Economic productivity
Some health interventions may hold special value as they
increase economic productivity more than other interven-
tions, thereby creating additional non-health welfare gains
for all through the tax system or other transfer mecha-
nisms [45,46]. Others think that the productivity argu-
ment discriminates against the non-productive [47]. Since
there is disagreement about these concerns, they are in-
consistently incorporated into cost-effectiveness analysis.
As a minimum, decision-makers should check whether
productivity gains are taken into account, and whether
this is not discriminating against the non-productive.
Care for others
Some health interventions hold special value because they
target people in the age where they typically take care of
others, e.g. children or elderly. In societies with an ex-
tended family structure and less reliance on the state to
provide welfare for children or the elderly, welfare for
others is widely accepted and relevant to consider.
Catastrophic health expenditures
Households may be pushed into poverty or forced into
deeper poverty because of high out-of-pocket expendi-
tures for health care [1,48]. Protection against catastrophic
health expenditures can reduce poverty and improve over-
all welfare in society [49]. Decision-makers could give pri-
ority to public financing of such high-costs interventions,
e, g, through subsidised provision or insurance coverage
(see Example 3) [50]. In high-income countries with fair
financing of health services, this criterion is typically given
little weight because insurance coverage is often broad
and interventions rarely impose large out-of pocket ex-
penditures [51]. In middle-income countries (and even in
some high-income countries), it is often the case that
treatment for many serious illnesses is not covered even in
these countries. This criterion is therefore relevant and
should always be considered.
Example 3: Dialysis to prevent catastrophic health
expenditures in Thailand:
In 2007 Thailand included peritoneal- and hemo-
dialysis for patients with end-stage renal disease in their
tax-based universal health insurance scheme. The incre-
mental cost-effectiveness ratio (ICER) of initial treatment
with peritoneal dialysis was in 2007 estimated to be US
$52,000 per quality-adjusted life-year (QALY) gained com-
pared with palliative care [52], and was by many inter-
preted as not cost-effective. Financial protection was
repeatedly used in the policy debate to nevertheless in-
cluding dialysis in the health insurance scheme: if dialysis
for end-stage renal disease would not be covered, it would
impose catastrophic health expenditures on patients and
thereby push them and their families into poverty.
This example shows that financial protection matters
to decision makers and the public, even for cost-
ineffective interventions. However, full coverage for all
in the universal plan would protect against catastrophic
expenditures, but it might also displace services that do
much more good. The example shows that the trade-off
between maximizing health and financial protection will
produce winners and losers, and it is not clear that the
health loss from replacing other services that are more
cost-effective and fair is well enough justified by finan-
cial protection of a few.
Conclusion
The GPS-Health does not provide a formula or blueprint
for equitable priority setting of health interventions but
should serve as input to priority setting processes [53].
Decision-makers should consider the checklist in con-
junction with cost-effectiveness analysis, and carefully
consider the criteria they find relevant to their health
system and political context.
Since efficiency, equity and financial protection are
considerations that sometimes conflict with each other,
decision makers need to weigh them against each other
and make trade-offs. It should be recognized that, in a
resource-constrained system, giving additional weight to
something or someone implies that something or someone
else will lose out. The inclusion of equity concerns must
therefore always take opportunity costs into consideration.
Use of this guidance is compatible with the use of more
quantitative approaches, for example multi criteria deci-
sion analysis, to consider equity in evaluations of health
interventions through explicit weighing [12,24,54,55].
Another example is the use of so-called equity or dis-
tributive weights, which can incorporate special priority
to the worst off [14,56]. A third example is a proposal in
UK to quantify the value of distributional impact for
value based assessments of health technologies [57].
Methods are also being developed to incorporate con-
cern for poverty and financial risk protection in ex-
tended cost-effectiveness analysis [58].
Yet, there may always be disagreement about the im-
portance of criteria when setting priorities between health
interventions. For this reason, ethicists have stressed the
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importance of fair processes, which allow key stakeholders
to agree on what is legitimate and fair. Key elements of a
fair process involves transparency about the grounds for
decisions; appeals to rationales that all can accept as rele-
vant to meeting health needs fairly; and procedures for re-
vising decisions in light of challenges to them. Together
these elements assure “accountability for reasonableness.”
[53]. The GPS-Health should therefore be seen as integral
to such legitimate processes.
The GPS-Health feeds into the international debate
about social value judgements [59] and the use of differ-
ent criteria for priority setting in health care, in two
ways. First, the present guidance can be considered as
complementary to published inventories and mapping of
all possibly relevant criteria [12,56] as it is based on in-
tense deliberative processes between experts on the rele-
vance of these criteria and ultimately consensus building
[12,60]. Second, many countries around the world men-
tion equity-related criteria in their policy frameworks on
the reimbursement of health interventions, but these are
sometimes ill-defined and not operationalized [61]. This
may be one reason why value judgements other than
health maximization are not routinely used in important
coverage decisions. The GPS-Health aims to overcome
this barrier by offering a ready-to-use checklist to
decision-makers. This may help them to make the right
decisions on the funding of one intervention and the re-
fusal to fund another.
Appendix: criteria excluded from the checklist
Life threatening conditions is a sub-category of severity
and is often a key concern in public debate about prior-
ity setting decisions. For example, cancer with metastasis
may be life threatening, and interventions that save or
extend life for people with such conditions may there-
fore be assigned very high priority by some. But threat
to life cannot be the sole condition of priority. Some-
times interventions with marginal benefits and extremely
high costs should not be prioritized. The underlying
concern is better captured by the severity criterion com-
bined with effectiveness considerations.
Age
This guidance does not propose age as an independent
criterion. The combination of criteria will indirectly
imply some priority to the young. Cost-effectiveness ana-
lysis will typically, but not always, favour interventions
targeting younger age groups. The productivity criterion
also indirectly assigns less value to health gained in old
age. Severity and past health loss may often, but not al-
ways, favour the young. The more general principle that
all persons should have a fair chance to live a long and
healthy life will in most cases favour the young, but the
justification is not age itself, but who the worst off are in
terms of lifetime health. The expert group did not con-
sider whether health gains for the very young should have
different marginal weights than for adults [45,62,63].
Individual responsibility for health
In some instances, potential beneficiaries have an exist-
ing health condition clearly associated with past choices
or a known risky behaviour with a clear association with
future health problems. It could be reasonable to consid-
ered whether the intervention has lower value because
individuals bears some responsibility and has ability to
pay for their own care. Whether governments should
also hold individuals responsible for choices that affect
health and risk is a controversial question. Health condi-
tions are generally due to a combination of background
factors, luck and behaviour, and it is therefore unaccept-
able to submit patients to differential health care access
or financial conditions, unless this respects their own
values and preferences [32,64-68].
Rarity of health condition
Rare conditions, i.e. those with a very low prevalence (<5
cases per 10 000), pose a special challenge for priority
setting. Rarity is in itself not ethically relevant. However,
rare conditions are often particularly costly to treat be-
cause product development costs can only be spread
over relative few patients, and interventions may there-
fore be cost-ineffective. Evidence may also be weak be-
cause a small patient population makes it difficult to
conduct high quality randomized clinical trials. To some
extent the cost problem and the documentation problem
are balanced by the fact that the value of treatments for
rare conditions is in many cases augmented by other
equity concerns, such as concerns for severity and con-
cerns for realization of potentials/fair chances. However,
this balancing occurs in far from all rare diseases. To en-
sure equal access to treatment for patients with rare dis-
eases it is therefore sometimes argued that there should
be a higher willingness to pay for treatments for rare
conditions than for treatments in general. The problem
is that this would give an advantage to patients with rare
diseases relative to patients with more common diseases
who are costly to treat for other reasons than rarity.
Altogether the group did not agree on how rare diseases
should be dealt with, but a majority wanted it excluded
from the main list of equity criteria on the grounds that
rarity is not a value per se.
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